BACKGROUND/AIM: Patients with locally advanced prostate cancer are generally treated with radiotherapy (RT) which can be combined with hormonal therapy. RT plus monotherapy with luteinizing hormone-releasing hormone (LHRH) analog triptorelin was compared to RT plus total androgen block (TAB).
PATIENTS AND METHODS: A retrospective study was carried out on patients with locally advanced prostate cancer comparing RT plus monotherapy versus RT plus TAB.
RESULTS: For overall survival, no differences between patients receiving RT with monotherapy and those treated with TAB were observed. A trend favoring use of TAB was found for progression-free survival. No differences in late gastrointestinal and genitourinary toxicities were reported.
CONCLUSION: This study suggests that monotherapy with LHRH is as effective as TAB, which is important in selecting appropriate treatment considering that TAB can have higher risks of adverse events and reduce the quality of life of patients.
- Androgen Antagonists/therapeutic use
- Antineoplastic Agents/therapeutic use
- Antineoplastic Agents, Hormonal/therapeutic use
- Combined Modality Therapy/methods
- Disease-Free Survival
- Gonadotropin-Releasing Hormone/analogs & derivatives
- Kaplan-Meier Estimate
- Middle Aged
- Proportional Hazards Models
- Prostatic Neoplasms/drug therapy
- Retrospective Studies
- Triptorelin Pamoate/therapeutic use